-
公开(公告)号：US20180256679A1
公开(公告)日：2018-09-13
申请号：US15975591
申请日：2018-05-09
IPC分类号： A61K38/17 , C07K14/705 , A61K38/10 , C12N5/0783
CPC分类号： A61K38/177 , A61K38/10 , A61K47/68 , A61K48/00 , C07K14/70592 , C07K16/18 , C07K2319/30 , C12N5/0637 , C12Q1/6883 , G01N33/505 , G01N33/6872
摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
-
公开(公告)号：US20170232061A1
公开(公告)日：2017-08-17
申请号：US15384137
申请日：2016-12-19
发明人： Esther Bandala Sanchez , James Dromey , Leonard Charles Harrison , Yuxia Zhang , Maryam Rashidi
IPC分类号： A61K38/17
CPC分类号： A61K38/177 , A61K38/10 , A61K47/68 , A61K48/00 , C07K14/70592 , C07K16/18 , C07K2319/30 , C12N5/0637 , C12Q1/6883 , G01N33/505 , G01N33/6872
摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
-
公开(公告)号：US10328124B2
公开(公告)日：2019-06-25
申请号：US15975591
申请日：2018-05-09
IPC分类号： A61K38/10 , A61K38/17 , C07K14/705 , C12N5/0783 , C07K16/18 , C12Q1/6883 , G01N33/50 , G01N33/68 , A61K47/68 , A61K48/00
摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
-
公开(公告)号：US20140308209A1
公开(公告)日：2014-10-16
申请号：US14351501
申请日：2012-11-15
发明人： Esther Bandala Sanchez , James Dromey , Leonard Charles Harrison , Yuxia Zhang , Maryam Rashidi
CPC分类号： A61K38/177 , A61K38/10 , A61K47/68 , A61K48/00 , C07K14/70592 , C07K16/18 , C07K2319/30 , C12N5/0637 , C12Q1/6883 , G01N33/505 , G01N33/6872
摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
摘要翻译： 本公开涉及可溶性CD52糖蛋白及其在治疗由效应T细胞调节的疾病中的用途，例如自身免疫性疾病如1型糖尿病。 本公开还涉及包含可溶性糖蛋白的融合蛋白与表达高水平的CD52的细胞，以及基于检测受试者中CD52表达水平的诊断方法。
-
公开(公告)号：US11123403B2
公开(公告)日：2021-09-21
申请号：US16547322
申请日：2019-08-21
IPC分类号： A61K38/17 , C12N5/0783 , A61K47/68 , C07K14/705 , C07K16/18 , C12Q1/6883 , G01N33/50 , G01N33/68 , A61K48/00 , A61K38/10
摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
-
公开(公告)号：US20190192624A1
公开(公告)日：2019-06-27
申请号：US16218287
申请日：2018-12-12
IPC分类号： A61K38/17 , C12N5/0783 , G01N33/50 , C12Q1/6883 , C07K16/18 , C07K14/705 , A61K47/68 , G01N33/68
CPC分类号： A61K38/177 , A61K38/10 , A61K47/68 , A61K48/00 , C07K14/70592 , C07K16/18 , C07K2319/30 , C12N5/0637 , C12Q1/6883 , G01N33/505 , G01N33/6872
摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
-
公开(公告)号：US10010582B2
公开(公告)日：2018-07-03
申请号：US15384137
申请日：2016-12-19
IPC分类号： A61K38/17 , C07K14/705 , A61K38/10 , C12N5/0783
CPC分类号： A61K38/177 , A61K38/10 , A61K47/68 , A61K48/00 , C07K14/70592 , C07K16/18 , C07K2319/30 , C12N5/0637 , C12Q1/6883 , G01N33/505 , G01N33/6872
摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
-
公开(公告)号：US09778269B2
公开(公告)日：2017-10-03
申请号：US14440703
申请日：2013-03-25
IPC分类号： A61K38/10 , G01N33/68 , G01N33/564 , C07K14/705 , C07K16/28 , G01N33/50 , C12N5/0783 , A61K38/00
CPC分类号： G01N33/6896 , A61K38/00 , C07K14/70592 , C07K16/2803 , C07K16/2863 , C07K16/2866 , C07K16/2893 , C07K2317/76 , C07K2319/30 , C12N5/0637 , G01N33/502 , G01N33/564 , G01N33/6872 , G01N33/6893 , G01N2333/70592 , G01N2800/26 , G01N2800/285 , G01N2800/50 , G01N2800/52
摘要： The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.
-
公开(公告)号：US20200078440A1
公开(公告)日：2020-03-12
申请号：US16547322
申请日：2019-08-21
发明人： Esther Bandala Sanchez , James Dromey , Leonard Charles Harrison , Yuxia Zhang , Maryam Rashidi
IPC分类号： A61K38/17 , G01N33/68 , G01N33/50 , C12Q1/6883 , C07K16/18 , C07K14/705 , A61K47/68 , C12N5/0783
摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
-
公开(公告)号：US10413589B2
公开(公告)日：2019-09-17
申请号：US16218287
申请日：2018-12-12
IPC分类号： A61K38/17 , C07K14/705 , A61K38/10 , C12N5/0783 , G01N33/50 , C12Q1/6883 , C07K16/18 , A61K47/68 , G01N33/68 , A61K48/00
摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type I diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.024 秒)
